Search Page

1

Cite

Share

NF-kappa B as a target for cancer therapy.

Melisi D, Chiao PJ. Melisi D, et al. Expert Opin Ther Targets. 2007 Feb;11(2):133-44. doi: 10.1517/14728222.11.2.133. Expert Opin Ther Targets. 2007. PMID: 17227230 Review.

Cite

Share

2

Cite

Share

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.

Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacopuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, Melisi D. Merz V, et al. Among authors: melisi d. Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32684989 Free PMC article.

Cite

Share

3

Cite

Share

Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer.

Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, Melisi D. Cavaliere A, et al. Among authors: melisi d. J Gastric Cancer. 2019 Dec;19(4):375-392. doi: 10.5230/jgc.2019.19.e39. Epub 2019 Nov 13. J Gastric Cancer. 2019. PMID: 31897341 Free PMC article. Review.

Cite

Share

4

Cite

Share

Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.

Gueorguieva I, Tabernero J, Melisi D, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA. Gueorguieva I, et al. Among authors: melisi d. Cancer Chemother Pharmacol. 2019 Nov;84(5):1003-1015. doi: 10.1007/s00280-019-03931-1. Epub 2019 Sep 3. Cancer Chemother Pharmacol. 2019. PMID: 31482224

Cite

Share

5

Cite

Share

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.

Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. Taieb J, et al. Among authors: melisi d, d esquermes n. ESMO Open. 2020 Jan;5(1):e000587. doi: 10.1136/esmoopen-2019-000587. ESMO Open. 2020. PMID: 31958291 Free PMC article.

Cite

Share

6

Cite

Share

Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.

Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, Melisi D. Merz V, et al. Among authors: melisi d. Clin Cancer Res. 2020 Sep 1;26(17):4661-4669. doi: 10.1158/1078-0432.CCR-20-0395. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532788

Cite

Share

7

Cite

Share

Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo.

Lupo F, Piro G, Torroni L, Delfino P, Trovato R, Rusev B, Fiore A, Filippini D, De Sanctis F, Manfredi M, Marengo E, Lawlor RT, Martini M, Tortora G, Ugel S, Corbo V, Melisi D, Carbone C. Lupo F, et al. Among authors: melisi d. Front Cell Dev Biol. 2020 Apr 28;8:308. doi: 10.3389/fcell.2020.00308. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32411709 Free PMC article.

Cite

Share

8

Cite

Share

Angiogenesis: a target for cancer therapy.

Tortora G, Melisi D, Ciardiello F. Tortora G, et al. Among authors: melisi d. Curr Pharm Des. 2004;10(1):11-26. doi: 10.2174/1381612043453595. Curr Pharm Des. 2004. PMID: 14754402 Review.

Cite

Share

9

Cite

Share

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. Melisi D, et al. Mol Cancer Ther. 2008 Apr;7(4):829-40. doi: 10.1158/1535-7163.MCT-07-0337. Mol Cancer Ther. 2008. PMID: 18413796 Free PMC article.

Cite

Share

10

Cite

Share

Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB.

Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, Evans DB, Chiao PJ. Melisi D, et al. Mol Cancer Res. 2009 May;7(5):624-33. doi: 10.1158/1541-7786.MCR-08-0201. Epub 2009 May 12. Mol Cancer Res. 2009. PMID: 19435817 Free PMC article.

Cite

Share